Spero Therapeutics Inc (SPRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.26M
Last updated: Nov 17, 2026 at 11:05 AM ET
Spero Therapeutics Inc (SPRO) Stock Forecast
Analysts expect Spero Therapeutics (SPRO) to earn -$0.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $258000. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.11.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 66.7% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.58
- EPS consensus, revenue $258000
- Fiscal year ending Dec 31, 2027
- -$0.11
- EPS consensus
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.58 | -$0.58 to -$0.58 | 1 | $258000 | $258000 to $258000 | 1 |
| Dec 31, 2027 | -$0.11 | -$0.88 to $0.67 | 2 | N/A | N/A | 1 |
Quarterly Estimates
The EPS consensus rises from -$0.21 for the quarter ending Dec 31, 2026 to -$0.14 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.21 | -$0.26 to -$0.15 | 4 |
| Mar 31, 2027 | -$0.14 | -$0.14 to -$0.14 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a profit of $0.67 to a loss.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.58 | -$0.29 | -$0.29 | -$0.29 | $0.67 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.11 | $0.67 | $0.67 | $0.67 | $0.76 | N/A |
Frequently Asked Questions About SPRO
What is the SPRO stock forecast?
Consensus analyst estimates put Spero Therapeutics's EPS at -$0.58 for the fiscal year ending Dec 31, 2026, on revenue of $258000. The consensus rating from 3 analysts is Buy.
How do analysts rate SPRO stock?
Of 3 analysts covering Spero Therapeutics, 0 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SPRO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.58, with estimates from -$0.58 to -$0.58 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.11, with estimates from -$0.88 to $0.67 from 2 analysts.
What revenue do analysts expect from Spero Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $258000, with estimates from $258000 to $258000.
How many analysts cover SPRO?
3 analysts rate Spero Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
SPRO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts